GRCE
Grace Therapeutics, Inc.Healthcare·Biotechnology
$2.57
$40M market cap
Revenue
$0.0M
Free Cash Flow
$-10.1M
Rev Growth
+0.0%
FCF Margin
0.0%
P/FCF
--
EV/FCF
--
Fwd EV/EBITDA
--
Fair Value
--
Upside
--
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma
2-Year Price History
$2.20-29.3%
Quarterly Financials & Projections
Quarterly Waterfall ($ M)
| Period | Rev | EBITDA | OpIn | NI | OCF | FCF | CapEx | Cash | Debt | Shares | ROIC | IntCov | EV/EBITDA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Act | 2026-Q3 | 0.0 | -3.4 | -3.4 | -3.2 | -2.2 | -2.2 | -0.0 | 18.7 | 0.0 | 16.9 | -70.6% | -- | -- |
| Act | 2026-Q2 | 0.0 | -0.9 | -2.5 | -0.9 | -3.2 | -3.2 | -0.0 | 16.9 | 0.0 | 15.9 | -58.7% | -- | -- |
| Act | 2026-Q1 | 0.0 | -3.1 | -3.1 | -3.4 | -1.8 | -1.8 | -0.0 | 20.0 | 0.0 | 15.9 | -67.7% | -- | -- |
| Act | 2025-Q4 | 0.0 | -0.4 | -3.2 | 0.6 | -3.0 | -3.0 | -0.0 | 22.1 | 0.0 | 13.7 | -40.0% | -- | -- |
Historical Valuation
Multiples vs the company's own history — cheap or rich relative to itself? Historical fiscal years, then TTM, then forward projections (E). Forward rows hold today's price against projected earnings, so the multiple compresses if the company grows into it.
| Year | Price | Rev Gr | EBITDA % | EBITDA | EV/EBITDA | EV/FCF | P/E | P/S |
|---|---|---|---|---|---|---|---|---|
| TTM | 2.57 | — | — | -8 | 0.0× | 0.0× | 0.0× | — |
EBITDA in reporting-currency $M. Historical multiples use year-end market cap (split-adjusted price history); TTM & forward years use today's.
Valuation & Metrics
Market Stats
Price$2.57
Market Cap$40M
Enterprise Value$21M
P/S Ratio0.0x
P/FCF--
EV/FCF--
FCF Margin (TTM)0.0%
FCF Yield-25.5%
Dividend Yield (TTM)--
Annual Dilution0.0%
CurrencyUSD
TTM Financial Snapshot
Revenue$0.0M
Net Income$-6.8M
Free Cash Flow$-10.1M
Revenue Growth (YoY)+0.0%
EBITDA Margin0.0%
Net Margin0.0%
FCF Margin0.0%
CapEx % of Revenue0.0%
SBC % of Revenue0.0%
ROIC-59.2%
WC Change % Rev0.0%
Interest Coverage--
Forward Outlook & Risk
Short Interest
Short % of Float--
Short Shares2.2M
Days to Cover1.4
Change (vs Prior)+12.9%
Need at least 2 settlement dates for chart
Employees
Headcount4
Revenue / Employee$0
Gross Profit / Employee$-1,529
Cash Runway
22.1months
WATCH
Institutional Ownership
Headline & net flow
NEUTRAL
Net flow · —still filing
No float data — flow unavailable.
Ownership composition
Active
49.5%(+24.6% YoY)
29 filers
hedge / family / endowment
Retail funds
—
Fidelity, Schwab, 401(k)
Passive
5.5%(+3.8% YoY)
2 filers
Vanguard, iShares, SPDR
Market makers
2.3%(+2.3% YoY)
3 filers
Citadel, Susquehanna
Insiders
—
Form 4 — latest per insider
ActiveRetail fundsPassiveMarket makersRetail direct
Top holders
| Fund | $ value | Cost basis | Δ QoQ | Δ YoY | α life | Fund AUM |
|---|---|---|---|---|---|---|
| HPM Partners LLC | $3.9M | $4.05 | +$2.0M | +$3.9M | -0.1% | $70.24B |
| Eversept Partners, LP | $3.5M | $4.63 | +$3.5M | +$3.5M | -0.3% | $1.52B |
| Nantahala Capital Management, LLC | $3.4M | $2.28 | −$2.1M | −$2.1M | -2.4% | $1.60B |
| BANK OF AMERICA CORP /DE/ | $2.3M | $3.74 | +$0 | +$0 | -0.1% | $1.36T |
| VANGUARD CAPITAL MANAGEMENT LLCPassive | $1.9M | $4.63 | +$1.9M | +$1.9M | — | $4.04T |
| RENAISSANCE TECHNOLOGIES LLC | $1.1M | $3.92 | +$528K | +$934K | +1.2% | $63.91B |
| JANE STREET GROUP, LLCMM | $774K | $4.63 | +$774K | +$774K | -0.1% | $92.10B |
| CITADEL ADVISORS LLC | $457K | $3.96 | +$261K | +$279K | -0.4% | $138.22B |
| MARSHALL WACE, LLP | $423K | $4.63 | +$423K | +$423K | +0.6% | $92.71B |
| Connective Capital Management, LLC | $391K | $4.63 | +$391K | +$391K | +2.4% | $121M |
| Quadrature Capital Ltd | $309K | $4.63 | +$309K | +$309K | +1.3% | $8.40B |
| XTX Topco Ltd | $292K | $4.07 | +$152K | +$292K | -1.9% | $5.74B |
| Birchview Capital, LP | $232K | $4.63 | +$232K | +$232K | -1.3% | $176M |
| Diametric Capital, LP | $184K | $4.63 | +$184K | +$184K | +1.1% | $381M |
| Pale Fire Capital SE | $175K | $4.63 | +$175K | +$175K | +0.7% | $1.14B |
| UBS Group AG | $122K | $4.63 | +$122K | +$122K | -0.3% | $562.11B |
| KESTRA PRIVATE WEALTH SERVICES, LLC | $60K | $4.63 | +$60K | +$60K | -0.5% | $8.06B |
| PRELUDE CAPITAL MANAGEMENT, LLC | $47K | $4.63 | +$47K | +$47K | +1.4% | $1.30B |
| OPPENHEIMER & CO INC | $46K | $4.63 | +$46K | +$46K | -0.1% | $8.20B |
| VANGUARD FIDUCIARY TRUST COPassive | $41K | $4.63 | +$41K | +$41K | — | $395.83B |
Cost basis is a volume-weighted estimate from accumulation periods within our 13F history; holders who built their position before our window started will show a stale basis. % above the cost basis is the unrealized gain at the current price.
Trading behavior
Smart-money alpha (lifetime, %/qtr)BULLISH
Holders
-0.45%
avg per quarter
Holders (ex-self)
-0.45%
excl. this stock
Buyers (this Q)
+0.06%
24 buyers · $0.01B in
Sellers (this Q)
-2.21%
4 sellers · $0.00B out
alpha coverage: 90% of $ has a lifetime-alpha record
Holder behavior on this stocksource: stock
On big dips (−10%+)
-3.8%
how holders react when this stock falls
On quiet Qs
-5.4%
−10% to +10% baseline
On rallies (+10%+)
-2.6%
how they react when this stock rises
Holders' portfolio flow this Q
+0.3%
inflows — adds are organic
Sellers' portfolio flow this Q
+1.6%
Sellers grew AUM elsewhere — opinionated cut of this stock.
▸ Compare to holder-profile behavior (across all their stocks)
Holder dip (any stock)
-2.5%
Holder mid (any stock)
-3.2%
Holder rally (any stock)
-6.8%
Biggest decreases this quarter
New buyers this quarter
Eversept Partners, LP+$0.00Bα-0.3VANGUARD CAPITAL MANAGEMENT LLC+$0.00BJANE STREET GROUP, LLC+$0.00Bα-0.1MARSHALL WACE, LLP+$0.00Bα+0.6Connective Capital Management, LLC+$0.00Bα+2.4Quadrature Capital Ltd+$0.00Bα+1.3Birchview Capital, LP+$0.00Bα-1.3Diametric Capital, LP+$0.00Bα+1.1Pale Fire Capital SE+$0.00Bα+0.7UBS Group AG+$0.00Bα-0.3
Top-5 holders · 75.7%
HPM Partners LLC--
Eversept Partners, LP--
Nantahala Capital Management, LLC--
BANK OF AMERICA CORP /DE/--
VANGUARD CAPITAL MANAGEMENT LLC--
Top Holders Over Time
5-year share-count history (top 10 holders by peak, incl. exited) + price
hover the chart for per-quarter detailprice (right axis)
Nantahala Capital Management, LLC728KHPM Partners LLC849KEversept Partners, LP757KAIGH Capital Management LLC—ADAR1 Capital Management, LLC—BANK OF AMERICA CORP /DE/495KRENAISSANCE TECHNOLOGIES LLC244KStonepine Capital Management, LLC—CITADEL ADVISORS LLC99KMARSHALL WACE, LLP91K
Analyst Coverage
Analyst Coverage
Price Targets
Last Quarter (1 analysts)$4.005560.0%
Last Year (1 analysts)$4.005560.0%
Current Price$2.57
Analyst Ratings
2
Buy: 2Consensus: Buy
Corporate
Order Flow (FINRA, ~3w lag)
40.7%retail+0.5pp
9.0%dark-4.2pp
week of 2026-04-13
Off-exchange volume from FINRA. Retail = non-ATS (wholesaler PFOF + broker internalization). Dark = ATS (dark-pool crossing networks, institutional). Lit-exchange = remainder.
Filing Risk Analysis
Filing Risk Scores
Grace Therapeutics, Inc.: Intangible-Heavy Balance Sheet Propelled by Frequent Related-Party Dilution
Overall Risk
7/10
Fraud
4/10
Dilution
9/10
Insolvency
6/10
Earnings Overstated
3/10
Hidden Liabilities
3/10
Legal
3/10
Audit Warnings
5/10
Hidden Upside
4/10
Contextually Acceptable
7/10